SEC Info - Alkermes plc - ‘8-K’ for 6/1/21

SEC Info℠

Home

Help

Please Sign In

Alkermes plc – ‘8-K’ for 6/1/21

On: Tuesday, 6/1/21, at 7:09am ET · For: 6/1/21 · Accession #: 1564590-21-30940 · File #: 1-35299

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/01/21  Alkermes plc                      8-K:8,9     6/01/21   11:244K                                   ActiveDisclosure/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     32K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     42K 
 7: R1          Document And Entity Information                     HTML     47K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 6: XML         XBRL Instance -- alks-8k_20210601_htm                XML     15K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- alks-20210601_lab                     XML     58K 
 5: EX-101.PRE  XBRL Presentations -- alks-20210601_pre              XML     35K 
 3: EX-101.SCH  XBRL Schema -- alks-20210601                         XSD     18K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    20K 
11: ZIP         XBRL Zipped Folder -- 0001564590-21-030940-xbrl      Zip     21K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C:

i false i Alkermes plc. i 0001520262 0001520262 2021-06-01 2021-06-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): i June 1, 2021

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

i Ireland	i 001-35299	i 98-1007018
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)


i Connaught House, i 1 Burlington Road
i Dublin 4, i Ireland i D04 C5Y6
(Address of principal executive offices)

Registrant's telephone number, including area code: + i 353- i 1-772-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

i ☐		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
i Ordinary shares, $0.01 par value		i ALKS		i Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


		Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On June 1, 2021, Alkermes plc issued a press release announcing that the U.S. Food and Drug Administration has approved LYBALVI^TM (olanzapine and samidorphan) for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. The press release is attached hereto as Exhibit 99.1 and is incorporated by reference in this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits





Exhibit
No.		Description

99.1		Press release issued by Alkermes plc dated June 1, 2021.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ALKERMES PLC

Date: June 1, 2021	By:	/s/ *David J. Gaffin*
		David J. Gaffin
		Secretary

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	6/1/21	None on these Dates
		List all Filings

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/28/21  Alkermes plc                      S-8         7/28/21    3:268K                                   ActiveDisclosure/FA

↑Top

Filing Submission 0001564590-21-030940 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)